Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of PD-L1-silenced DC vaccine combined with CIK after surgery for gastric cancer
ChiCTR1800015690Phase 2Not yet recruiting
- Sponsor
- Lanzhou University
- Start
- May 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PD-L1-silenced dendritic cell vaccine in gastric cancer (GC) (3 arms), sponsored by Lanzhou University. Primary endpoints: Dendritic cell surface markers, CIK surface markers and 9 more. Planned start May 2018; status: not yet recruiting.
02
Drugs
PD-L1-silenced dendritic cell vaccine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1800015690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015690.